Rhumbline Advisers Boosts Stock Holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN)

Rhumbline Advisers grew its stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) by 3.0% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 128,244 shares of the company’s stock after buying an additional 3,734 shares during the period. Rhumbline Advisers owned 0.13% of Dyne Therapeutics worth $3,021,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in DYN. Quantbot Technologies LP purchased a new stake in Dyne Therapeutics during the third quarter valued at about $34,000. Point72 DIFC Ltd acquired a new position in shares of Dyne Therapeutics in the 3rd quarter valued at about $36,000. US Bancorp DE lifted its stake in shares of Dyne Therapeutics by 776.9% in the 3rd quarter. US Bancorp DE now owns 1,368 shares of the company’s stock valued at $49,000 after purchasing an additional 1,212 shares in the last quarter. KBC Group NV grew its holdings in shares of Dyne Therapeutics by 53.4% during the 3rd quarter. KBC Group NV now owns 2,157 shares of the company’s stock worth $77,000 after purchasing an additional 751 shares during the period. Finally, Quest Partners LLC increased its position in Dyne Therapeutics by 898.3% during the 3rd quarter. Quest Partners LLC now owns 3,434 shares of the company’s stock worth $123,000 after purchasing an additional 3,090 shares in the last quarter. 96.68% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

DYN has been the topic of a number of recent research reports. HC Wainwright reduced their price target on shares of Dyne Therapeutics from $55.00 to $46.00 and set a “buy” rating on the stock in a research report on Friday. Chardan Capital restated a “buy” rating and set a $50.00 target price on shares of Dyne Therapeutics in a report on Friday. Guggenheim reaffirmed a “buy” rating on shares of Dyne Therapeutics in a research report on Friday, January 24th. Piper Sandler cut their price objective on Dyne Therapeutics from $53.00 to $48.00 and set an “overweight” rating on the stock in a research report on Friday. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $45.00 target price on shares of Dyne Therapeutics in a research report on Tuesday, January 14th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $48.64.

Insider Transactions at Dyne Therapeutics

In other Dyne Therapeutics news, insider Oxana Beskrovnaya sold 2,598 shares of the stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $13.95, for a total transaction of $36,242.10. Following the transaction, the insider now owns 199,087 shares of the company’s stock, valued at $2,777,263.65. This trade represents a 1.29 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Richard William Scalzo sold 1,455 shares of Dyne Therapeutics stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $28.12, for a total value of $40,914.60. Following the completion of the transaction, the senior vice president now owns 127,078 shares of the company’s stock, valued at approximately $3,573,433.36. The trade was a 1.13 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 6,387 shares of company stock valued at $142,789. Insiders own 20.77% of the company’s stock.

Dyne Therapeutics Stock Up 3.3 %

Shares of NASDAQ DYN opened at $13.61 on Friday. The business has a 50 day moving average price of $16.98 and a two-hundred day moving average price of $27.61. Dyne Therapeutics, Inc. has a fifty-two week low of $12.87 and a fifty-two week high of $47.45. The firm has a market cap of $1.39 billion, a PE ratio of -3.82 and a beta of 1.11.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings results on Tuesday, March 4th. The company reported ($0.88) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.04. On average, analysts anticipate that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current year.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.